Is hyaluran a biomarker in patients without sepsis-related liver injury?

Creative Commons License

Bahar İ., Elay G., BAYRAM A.

Eastern Journal of Medicine, vol.24, no.3, pp.283-288, 2019 (Refereed Journals of Other Institutions) identifier

  • Publication Type: Article / Article
  • Volume: 24 Issue: 3
  • Publication Date: 2019
  • Doi Number: 10.5505/ejm.2019.94899
  • Title of Journal : Eastern Journal of Medicine
  • Page Numbers: pp.283-288


© 2019, Yuzuncu Yil Universitesi Tip Fakultesi. All rights reserved.The aim of the present study is to evaluate the value of hyaluronan (HA) as a biomarker of sepsis in patients not showing sepsis-associated liver dysfunction and to investigate the relationship between HA level and disease severity. Sepsis patients that had been followed-up between 2015 and 2016 in intensive care units (ICU) of Erciyes University Hospital were included in this prospective study. Sepsis was defined according to the 2013 Sepsis Survival Campaign Guidelines. The patients were classified as sepsis, severe sepsis, and septic shock. Blood samples were collected from the patients on the first and the third days to measure the HA level. The demographic characteristics, the duration of intensive care unit stay, and mortality data of the patient and the control groups were analyzed. A total of 46 patients and 30 control subjects were evaluated. HA levels were found to be higher in the sepsis group than the others. HA was neither a predictor of the disease mortality, nor was it correlated with the inflammatory markers, C-reactive protein (CRP), and procalcitonin (PCT). HA is not a sepsis biomarker in the patients with sepsis who do not show sepsis-associated liver dysfunction.